書誌事項
- タイトル別名
-
- Clinical Applications and the Effect of Mexiletine on Refractory Epilepsies.
この論文をさがす
抄録
Twenty-four patients with refractory epilepsy were treated with mexiletine as an additional antiepileptic drug. As the initial responses, seizures were decreased by 50% or more in 7 (46.7%) of 15 patients with symptomatic partial epilepsy (SPE), in none of 7 with symptomatic generalized epilepsy (SGE), and in 1 of 2 with undetermined epilepsy. Seizures increased in 3 patients (20.0%) with SPE, and in 3 (42.9%) with SGE. Concerning seizure types, mexiletine had significant effects on 1 of 2 patients with simple partial seizures, on 7 of 13 with complex partial seizures, on 1 of 5 with secondarily generalized seizures, and on 1 of 8 with tonic seizures. No patients with a myoclonic seizure or atypical absence improved. Exacerbation of the seizures was observed in 2 of 13 patients with complex partial seizures, in 1 of 5 with secondarily generalized seizures, in 3 of 8 with tonic seizures, and in 2 of 3 with myoclonic seizures. Partial seizures were controlled well, whereas generalized seizures sometimes worsened. EEG improved in 3 patients with SPE ; decrease of focal spikes in 2 patients and disappearance of secondary generalization in 1. Follow- up for more than 3 months showed seizures to be lessened in 2 patients. Mexiletine is useful for the treatment of refractory epilepsies, especially SPE.
収録刊行物
-
- 脳と発達
-
脳と発達 32 (1), 29-34, 2000
THE JAPANESE SOCIETY OF CHILD NEUROLOGY
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679528872832
-
- NII論文ID
- 130004183361
- 10005655271
-
- NII書誌ID
- AN0020232X
-
- ISSN
- 18847668
- 00290831
-
- PubMed
- 10655748
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可